• 1
    Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl 2005; 11: 716732.
  • 2
    Camci C, Gurakar A, Rose J, Rizvi S, Wright H, Bader T, et al. Liver transplantation for hepatitis B in the United States. Transplant Proc 2005; 37: 43504353.
  • 3
    McGory R. Pharmacoeconomic analysis of HBV liver transplant therapies. Clin Transplant 2000; 14( Suppl 2): 2938.
  • 4
    Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004; 10: S74S85.
  • 5
    Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34: 903910.
  • 6
    Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2: 11041108.
  • 7
    Rehermann B, Fowler P, Sidney J, Person J, Redeker A, Brown M, et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995; 181: 10471058.
  • 8
    Rehermann B, Lau D, Hoofnagle JH, Chisari FV. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 1996; 97: 16551665.
  • 9
    Penna A, Artini M, Cavalli A, Levrero M, Bertoletti A, Pilli M, et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996; 98: 11851194.
  • 10
    Bertoletti A, Ferrari C. Kinetics of the immune response during HBV and HCV infection. Hepatology 2003; 38: 413.
  • 11
    Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000; 191: 12691280.
  • 12
    Webster GJ, Reignat S, Brown D, Ogg GS, Jones L, Seneviratne SL, et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004; 78: 57075719.
  • 13
    Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, et al. Characterization of HBV-specific T cell dysfunction in chronic HBV infection. J Virol 2007; 81: 42154225.
  • 14
    Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102: 968975.
  • 15
    Boni C, Penna A, Bertoletti A, Lamonaca V, Rapti I, Missale G, et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003; 39: 595605.
  • 16
    Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001; 33: 963971.
  • 17
    Murakami R, Amada N, Sato T, Orii T, Kikuchi H, Haga I, et al. Reactivation of hepatitis and lamivudine therapy in 11 HBsAg-positive renal allograft recipients: a single centre experience. Clin Transplant 2006; 20: 351358.
  • 18
    Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, Costa J. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982; 96: 447449.
  • 19
    Reed EC, Myerson D, Corey L, Meyers JD. Allogeneic marrow transplantation in patients positive for hepatitis B surface antigen. Blood 1991; 77: 195200.
  • 20
    Bihl FK, Loggi E, Chisholm JV 3rd, Hewitt HS, Henry LM, Linde C, et al. Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti-CD3 mAb T-cell expansion and “RecycleSpot”. J Transl Med 2005; 3: 20.
  • 21
    Frahm N, Korber BT, Adams CA, Szinger JJ, Draenert R, Addo MM, et al. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol 2004; 78.
  • 22
    Calef C, Thakallapally R, Lang D, Brander C, Goulder P, Yang O, Korber B. PeptGen: designing peptides for immunological studies and application to HIV consensus sequences. In: KorberBT, BranderC, HaynesBF, KoupR, KuikenC, MooreJP, et al., eds. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory: Los Alamos, NM. 2000. pp. 1-63100.
  • 23
    Draenert R, Altfeld M, Brander C, Basgoz N, Corcoran C, Wurcel AG, et al. Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. J Immunol Methods 2003; 275: 1929.
  • 24
    Galibert F, Mandart E, Fitoussi F, Tiollais P, Charnay P. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature 1979; 281: 646650.
  • 25
    Kidd-Ljunggren K, Miyakawa Y, Kidd AH. Genetic variability in hepatitis B viruses. J Gen Virol 2002; 83: 12671280.
  • 26
    Kaufmann DE, Bailey PM, Sidney J, Wagner B, Norris PJ, Johnston MN, et al. Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J Virol 2004; 78: 44634477.
  • 27
    Norris PJ, Moffett HF, Brander C, Allen TM, O'Sullivan KM, Cosimi LA, et al. Fine specificity and cross-clade reactivity of HIV type 1 Gag-specific CD4+ T cells. AIDS Res Hum Retroviruses 2004; 20: 315325.
  • 28
    Draenert R, Brander C, Yu XG, Altfeld M, Verrill CL, Feeney ME, et al. Impact of intrapeptide epitope location on CD8 T cell recognition: implications for design of overlapping peptide panels. AIDS 2004; 18: 871876.
  • 29
    Frahm N, Yusim K, Suscovich TJ, Adams S, Sidney J, Hraber P, et al. Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol 2007; 37: 24192433.
  • 30
    Bihl F, Narayan M, Chisholm JV 3rd, Henry LM, Suscovich TJ, Brown EE, et al. Lytic and latent antigens of the human gammaherpesviruses Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus induce T-cell responses with similar functional properties and memory phenotypes. J Virol 2007; 81: 49044908.
  • 31
    Bihl F, Mosam A, Henry LN, Chisholm JV 3rd, Dollard S, Gumbi P, et al. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma. AIDS 2007; 21: 12451252.
  • 32
    Ferrari C, Penna A, Bertoletti A, Valli A, Antoni AD, Giuberti T, et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990; 145: 34423449.
  • 33
    Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 1992; 176: 157168.
  • 34
    Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994; 93: 230239.
  • 35
    Bertoletti A, Gehring AJ. The immune response during hepatitis B virus infection. J Gen Virol 2006; 87: 14391449.
  • 36
    Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13: 4653.
  • 37
    Woodberry T, Suscovich TJ, Henry LM, Davis JK, Frahm N, Walker BD, et al. Differential targeting and shifts in the immunodominance of Epstein-Barr virus–specific CD8 and CD4 T cell responses during acute and persistent infection. J Infect Dis 2005; 192: 15131524.
  • 38
    Woodberry T, Suscovich TJ, Henry LM, Martin JN, Dollard S, O'Connor PG, et al. Impact of Kaposi sarcoma-associated herpesvirus (KSHV) burden and HIV coinfection on the detection of T cell responses to KSHV ORF73 and ORF65 proteins. J Infect Dis 2005; 192: 622629.
  • 39
    Simitsek PD, Campbell DG, Lanzavecchia A, Fairweather N, Watts C. Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants. J Exp Med 1995; 181: 19571963.
  • 40
    Watts C, Lanzavecchia A. Suppressive effect of antibody on processing of T cell epitopes. J Exp Med 1993; 178: 14591463.
  • 41
    Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443: 350354.
  • 42
    Marinos G, Rossol S, Carucci P, Wong PY, Donaldson P, Hussain MJ, et al. Immunopathogenesis of hepatitis B virus recurrence after liver transplantation. Transplantation 2000; 69: 559568.
  • 43
    Klein I, Crispe IN. Complete differentiation of CD8+ T cells activated locally within the transplanted liver. J Exp Med 2006; 203: 437447.
  • 44
    Rosen HR, Hinrichs DJ, Leistikow RL, Callender G, Wertheimer AM, Nishimura MI, Lewinsohn DM. Cutting edge: identification of hepatitis C virus-specific CD8+ T cells restricted by donor HLA alleles following liver transplantation. J Immunol 2004; 173: 53555359.